-+ 0.00%
-+ 0.00%
-+ 0.00%
Energenesis Biomedical and Taiwan Tanabe Seiyaku Enter Joint Development Agreement for ENERGI-F703DFU
Share
Listen to the news

KEY HIGHLIGHTS

TAIPEI, Aug. 6, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has entered into a joint development agreement with Taiwan Tanabe Seiyaku Co., Ltd. (Taiwan Tanabe), the wholly owned subsidiary of Tanabe Pharma Corporation, for ENERGI-F703DFU, Energenesis' investigational topical drug for diabetic foot ulcers (DFU).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending